viewShield Therapeutics PLC

Full interview: Shield Therapeutics ties up US$63mln deal for Feraccru in China

Shield Therapeutics (LON:STX) has signed an exclusive agreement worth up to US$63mln for its iron deficiency treatment Feraccru to be sold in China. Chief Executive Carl Sterritt came to talk to us at Proactive London and he couldn't hide his enthusiasm at the deal making it over the line, having worked diligently on it for more than a year. News here on when the drug will go commercial, what the terms of the agreeement are and a whisper on discussions with major US partners too.
The deal with ASK Pharm (Beijing Aosaikang Pharmaceutical), covers China, Hong Kong, Macau and Taiwan and will involve an upfront payment of US$11.4mln and up to US$51.4mln in milestone and royalties.

Quick facts: Shield Therapeutics PLC

Price: 83.8067 GBX

Market: LSE
Market Cap: £98.21 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics PLC: Proactive One2One Virtual Event

Shield Therapeutics PLC's (LON:STX) Tim Watts pitches the company to investors at the Proactive One2One Virtual Event. Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group’s lead...

on 8/6/20

2 min read